Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
EBITDA for the quarter rose from $260 million to $272 million.Dr. Reddy's Laboratories Ltd (NYSE:RDY) reported Tuesday a second-quarter 2025 net income of $160 million, down from $177 million a year ago.
印度力達製藥有限公司（紐約證券交易所: RDY）報告稱，2025年第二季度淨利潤爲16000萬美元，低於一年前的17700萬美元。
Revenue increased from $821 million to $957 million — almost a 16.6% jump.
營業收入從82100萬美元增至95700萬美元 — 幾乎增長了16.6%。
The strong revenue growth during the quarter was primarily driven by growth in global generics revenues. The sequential growth was led by global generics revenues in Emerging Markets, India, Europe and Pharmaceutical Services and Active Ingredients (PSAI).
本季度強勁營收增長主要來自全球仿製藥收入的增長。新興市場、印度、歐洲和藥品服務及活性成分（PSAI）的全球仿製藥收入引領了環比增長。
EBITDA for the quarter rose from $260 million to $272 million.
本季度EBITDA從26000萬美元上升至27200萬美元。
"We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell and related brands," said co-chair GV Prasad.
共同主席GV Prasad表示：「我們交出了另一個良好的季度，並在所有業務領域保持了增長勢頭。我們在未來增長驅動因素上取得了進展，啓動了與雀巢的合作創業項目，並完成了對尼古丁片（Nicotinell）及相關品牌的收購。」
Global generics revenues during the second quarter reached 71.6 billion rupees, showing a 17% year-over-year growth, driven by improved sales volumes and new product launches.
第二季度全球仿製藥收入達到716億盧比，同比增長17%，這主要得益於銷售量的提升以及新產品的推出。
North American sales increased 17% (a sequential decline of 3%) to 37.3 billion rupees. YoY growth was largely due to increased sales volumes, partly offset by price erosion. The sequential decline was due to a decrease in sales volumes.
北美銷售額增長了17%（環比下降3%）至373億盧比。同比增長主要是由於銷售量增加，部分被價格侵蝕所抵消。環比下降是由於銷售量減少。
Gross Margin at 59.6% (GG: 63.1 %, PSAI: 30.0%), a YoY increase of 92 basis points (bps) and a QoQ decline of 81 bps. The YoY increase was due to an improvement in product mix and overhead leverage, partly offset by price erosion. On a sequential basis, the decline was primarily due to changes in the mix.
毛利率爲59.6%（全球仿製藥：63.1%，PSAI：30.0%），同比增長92個點子（bps），環比下降81個點子。同比增長主要歸因於產品組合和製造費用的改善，部分被價格侵蝕所抵消。環比下降主要是由於產品組合的變化。
Price Action: Dr. Reddy's Laboratories is up 4.81% at $15.51 during the premarket session at last check Tuesday.
股價走勢：在上週二最後一次檢查時，Dr. Reddy's Laboratories的股價在盤前交易中上漲了4.81%，報15.51美元。
- Short Squeeze – GlobalFoundries Stock Soars On Q3 Earnings Beat, Strong Q4 Outlook
- 開空迫使：GlobalFoundries股價在第三季度業績超出預期，強勁的第四季度展望使其大幅上漲。
譯文內容由第三人軟體翻譯。
